Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung08: Dato-DXd plus pembrolizumab versus pembrolizumab in first-line PD-L1-high advanced NSCLC
jRCT2061210074Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Dato-DXd + pembrolizumab with Pembrolizumab (2 arms). Primary endpoints: Progression-free survival by blinded independent central review in participants with non-squamous histology and Overall survival in participants with non-squamous histology. Started Mar 2022; status: active, not recruiting.
02
Drugs
datopotamab deruxtecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061210074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210074.